ACCENTIA BIOPHARMACEUTICALS INC Research and Development Expense
ACCENTIA BIOPHARMACEUTICALS INC reported Research and Development Expense of $5.24 million for the 12-month period ending 2012-09-30, per its 10-K filed 2012-12-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2012-12-26
- ACCENTIA BIOPHARMACEUTICALS INC research and development expense for the quarter ending 2012-09-30 was $1.34M, a 54.94% increase year-over-year.
- ACCENTIA BIOPHARMACEUTICALS INC research and development expense for the quarter ending 2012-06-30 was $1.13M, a 72.19% increase year-over-year.
- ACCENTIA BIOPHARMACEUTICALS INC research and development expense for the quarter ending 2012-03-31 was $1.81M, a 332.47% increase year-over-year.
- ACCENTIA BIOPHARMACEUTICALS INC research and development expense for the quarter ending 2011-12-31 was $961.66K, a 227.32% increase year-over-year.
- ACCENTIA BIOPHARMACEUTICALS INC research and development expense for fiscal 2012 was $5.24M, a 134.71% increase from fiscal 2011.
- ACCENTIA BIOPHARMACEUTICALS INC research and development expense for fiscal 2011 was $2.23M, a 71.12% increase from fiscal 2010.
- ACCENTIA BIOPHARMACEUTICALS INC research and development expense for fiscal 2010 was $1.30M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2012-09-30 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2012-12-26 | $2.47M derived: sum of 2 quarters · filed 2012-12-26 | $4.27M derived: sum of 3 quarters · filed 2012-12-26 | $5.24M 10-K · filed 2012-12-26 |
| 2012-06-30 | $1.13M 10-Q · filed 2012-08-14 | $2.94M derived: sum of 2 quarters · filed 2012-08-14 | $3.90M 10-Q · filed 2012-08-14 | $4.76M derived: sum of 4 quarters · filed 2012-12-26 |
| 2012-03-31 | $1.81M 10-Q · filed 2012-05-15 | $2.77M 10-Q · filed 2012-05-15 | $3.63M derived: sum of 3 quarters · filed 2012-12-26 | $4.29M derived: sum of 4 quarters · filed 2012-12-26 |
| 2011-12-31 | $961.66K 10-Q · filed 2012-02-10 | $1.82M derived: sum of 2 quarters · filed 2012-12-26 | $2.48M derived: sum of 3 quarters · filed 2012-12-26 | $2.90M derived: sum of 4 quarters · filed 2012-12-26 |
| 2011-09-30 | $861.86K derived: 10-K 12 month − 10-Q 9 month · filed 2012-12-26 | $1.52M derived: sum of 2 quarters · filed 2012-12-26 | $1.94M derived: sum of 3 quarters · filed 2012-12-26 | $2.23M 10-K · filed 2012-12-26 |
| 2011-06-30 | $657.23K 10-Q · filed 2012-08-14 | $1.08M derived: sum of 2 quarters · filed 2012-08-14 | $1.37M 10-Q · filed 2012-08-14 | $1.71M derived: sum of 4 quarters · filed 2012-08-14 |
| 2011-03-31 | $417.85K 10-Q · filed 2012-05-15 | $711.65K 10-Q · filed 2012-05-15 | $1.05M derived: sum of 3 quarters · filed 2012-05-15 | $1.39M derived: sum of 4 quarters · filed 2012-05-15 |
| 2010-12-31 | $293.80K 10-Q · filed 2012-02-10 | $635.93K derived: sum of 2 quarters · filed 2012-02-10 | $971.89K derived: sum of 3 quarters · filed 2012-02-10 | |
| 2010-09-30 | $342.13K derived: 10-K 12 month − 10-Q 9 month · filed 2011-12-19 | $678.10K derived: sum of 2 quarters · filed 2011-12-19 | $1.30M 10-K · filed 2011-12-19 | |
| 2010-06-30 | $335.96K 10-Q · filed 2011-08-12 | $961.50K 10-Q · filed 2011-08-12 |